Solvonis Therapeutics (LON: SVNS) shares surged 13% in early trading after the company announced positive preclinical pharmacokinetic data for its lead Alcohol Use Disorder treatment candidate, SVN-002, marking an important step towards U.S. clinical development.
SVN-002 is the company’s proprietary oral thin-film esketamine formulation designed for supervised treatment of moderate-to-severe Alcohol Use Disorder. The treatment is being developed under the FDA’s 505(b)(2) regulatory pathway, which could allow Solvonis to leverage existing safety and efficacy data from Johnson & Johnson’s approved esketamine product, Spravato®.
The latest study demonstrated that SVN-002’s combined sublingual-buccal delivery method generated rapid systemic exposure to esketamine and produced metabolite levels comparable to those seen with intranasal esketamine. The findings are considered important because exposure levels were specifically highlighted by the FDA as a key requirement during earlier regulatory discussions.
Management believes the data strengthen the planned Investigational New Drug application and support the scientific bridge required for the 505(b)(2) approval strategy.
Following the positive results, Solvonis plans to engage further with the FDA to determine the scope of the remaining toxicology work before submitting an IND application. Subject to regulatory feedback, the company intends to advance SVN-002 into a Phase 2b clinical trial in patients suffering from moderate-to-severe Alcohol Use Disorder in the United States.
The commercial opportunity is substantial. Solvonis estimates that around 15 million adults in the U.S. fall within its target patient population, significantly larger than the estimated 2.8 million treatment-resistant depression patients served by Spravato. Johnson & Johnson reported global Spravato sales of approximately $1.7 billion during 2025.
Chief Executive Anthony Tennyson described the results as an important technical and regulatory milestone, stating that the data provide a strong foundation for the next stage of FDA engagement and support the company’s goal of progressing SVN-002 into late-stage clinical development.
Chief Scientific Officer Professor David Nutt added that the pharmacokinetic profile observed was highly encouraging and supports the rationale for SVN-002 as a transmucosal thin-film treatment for Alcohol Use Disorder.
For investors, the update represents a significant de-risking event for the programme and reinforces Solvonis’ strategy of pursuing a potentially faster and more capital-efficient development pathway in a large, underserved market.
